Injectafer is the brand name of ferric carboxymaltose. Injectafer is an intravenous treatment for iron deficiency anemia (IDA) in adult patients who cannot be successfully treated with iron pills, or suffer from non-dialysis dependent chronic kidney disease.
Injectafer was originally available in Europe (under the brand name Ferinject) and first marketed in the United States in 2013, where it is currently sold by pharmaceutical manufacturer Daiichi Sankyo. Unfortunately, Injectafer has been linked to a very serious condition known as hypophosphatemia (HPP).
Studies show that Injectafer is much more dangerous than other similar treatments (such as Monofer). These studies show a significant link between Injectafer and an increased risk of severe hypophosphatemia. Examples of these studies include:
Contact our Injectafer hypophosphatemia attorneys, free of charge, for more information.
Injectafer has been linked to an increased risk of hypophosphatemia. Hypophosphatemia is basically low serum phosphate levels (lack of vital phosphorous in the blood). Severe hypophosphatemia, especially over time, can have a dramatic effect on bones, muscles and the cardiovascular system. Injectafer hypophosphatemia has been linked to serious medical conditions, including:
Accordingly, in February 2020, the United States Food and Drug Administration approved revised labeling for Injectafer that includes additional warnings regarding hypophosphatemia.
If you believe you have taken Injectafer and suffered one of these Injectafer hypophosphatemia injuries, an experienced Injectafer hypophosphatemia attorney at Stark & Stark can help you assess your potential claims. Contact a Stark & Stark Injectafer hypophosphatemia attorney now for a free consultation.
Lawsuits against the manufacturers of Injectafer have been filed in federal court in the United States District Court, Eastern District of Pennsylvania, and state court in the Philadelphia County Court of Common Pleas. These lawsuits claim that the manufacturers of Injectafer knew of its dangerous side-effects and link to hypophosphatemia, but failed to properly warn patients. Based upon these facts, it is expected that many more lawsuits across the nation will follow.
If you or a loved one have taken Injectafer and suffered a hypophosphatemia injury, it is strongly recommended that you seek counsel with an Injectafer hypophosphatemia attorney, who is knowledgeable in Injectafer hypophosphatemia lawsuits, claims, and injuries.
Do not wait – there are different deadlines and statutes of limitations that apply to your potential claim. Let us review your potential claim at no cost to you. Contact a Stark & Stark Injectafer hypophosphatemia attorney immediately.
Stark & Stark is committed to holding drug and medical device manufacturers liable when their products improperly endanger the public. If you or a member of your family has suffered injuries from taking Injectafer, you may be entitled to compensation through the litigation process or via settlement.
We are not a marketing group. Stark & Stark is a law firm comprised of experienced trial lawyers. Stark & Stark is a national law firm pursuing thousands of cases throughout the country. We have been in business for over 80 years and have over 100 attorneys in offices located throughout New Jersey, Pennsylvania and New York.
Our Injectafer hypophosphatemia lawsuit attorneys are experienced in pharmaceutical litigation cases and in negotiating with medical device and pharmaceutical settlement representatives. Let us help you.
Please contact Stark & Stark to speak with an Injectafer hypophosphatemia attorney, free of charge, who can help assess any claims that you may have and to help you understand the Injectafer hypophosphatemia settlement and lawsuit process. Allow our Injectafer attorneys to help you today.
Stark & Stark Recognized with Community Partner Award by Mercer County Community College Foundation
Stark & Stark is proud to announce that the firm has been recognized with the Community Partner Award by the Mercer County Community College...Carin A. O’Donnell, Esq. Inducted as 2026-2027 President of the Pennsylvania Association for Justice
Stark & Stark is proud to announce that Carin A. O'Donnell, Esq. was sworn in as the 2026-2027 President of the Pennsylvania Association for...Stark & Stark’s Thomas S. Onder, Esq. Receives 2026 ICSC Trustees’ Distinguished Service Award
Stark & Stark is proud to announce that Thomas S. Onder, Esq., Shareholder and Chair of the Firm’s Shopping Center & Retail Development...Our Values Remain: A Message on the Closing of Diversity Lab
Stark & Stark is saddened and disappointed to learn that Diversity Lab, the organization that created and manages the Mansfield Certification...Retail Development Team Secures Major Recovery for Landlord Client Amid Bankruptcy Dispute
Our Shopping Center and Retail Development Group recently secured a multi-million-dollar settlement for a commercial landlord client' s property...